

PATENT APPLICATION

UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Chen et al.

Serial No.:

10/046,681

Group Art Unit No.:

1614

Filed:

January 10, 2002

Examiner: n/a

For:

Substituted Alkylamine Derivatives and Methods of

Use

Docket No.:

A-733A

Warmon 1/24/a

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

As a means of complying with the duty of disclosure, applicant(s) submit(s) a "List of References Cited by Applicant" on a modified PTO-1449 form and provide(s) a copy of each of the listed references for consideration by the Examiner.

Applicant's(s') position regarding this information and its relevancy remains unchanged.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).

Applicant(s) request(s) consideration of this information and passage of the application to issue.

CERTIFICATE OF MAILING

1

I hereby certify that this correspondence is being denosited with the United States Postal Service

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,

Joseph W. Bulock

Attorney/Agent for Applicant(s)

Registration No.: 37,103 Phone: (805) 447-7966 Date: June 10, 2002

Please send all future correspondence to:

US Patent Operations/ JWB cpb Dept. 4300, M/S 27-4-A AMGEN INC. One Amgen Center Drive Thousand Oaks, California 91320-1799

Sheet Of

Atty. Docket No. Applicant

Serial No. A-733A

10/046.681

1614

LIST OF REFERENCES CITED BY APPLICATION

(Use several sheets if necessary)

Modified Form PTO-1449

Chen et al. Filing Date Group January 10, 2002

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A1	3,226,394	12/28/65	Schipper			
	A2	5,532,358	7/2/96	Kelly			
	A3	6,140,351	10/31/00	Arnaiz et al			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-		LATION
-		0.400.007	0/04/70			CLASS	YES	NO V
	B1	2 168 227	8/31/73	FR				X
	B2	WO 96/41795	12/27/96	PCT				
	B3	WO 98/24771	6/11/98	PCT				
	B4	EP 0 947 500 A1	10/6/99	EP				
	B5	WO 98/45268	10/15/98	PCT				
	B6	WO 99/32477	7/1/99	PCT	Ħ			
	B7	WO 99/62885	12/9/99	PCT	TECH :		2	
	B8	WO 00/02851	1/20/00	PCT	CENTER	Z C	5	
	В9	WO 00/27819	5/18/00	PCT	I	30]	X
	B10	WO 00/27820	5/18/00	PCT	600/	002	Ì	
	B11	WO 00/39111	7/6/00	PCT	600/2900	-		
	B12	WO 00/39117	7/6/00	PCT				
	B13	P2000 256358A	9/19/00	JP				X
·	B14	WO 01/29009 A1	4/26/01	PCT				
	B15	WO 01/30745 A1	5/3/01	PCT				
	B16	WO 01/55114 A1	8/2/01	PCT				
	B17	WO 01/55115 A1	8/2/01	PCT				
	B18	WO 01/81311 A1	11/1/01	PCT				X
	B19	WO 01/85715 A2	11/15/01	PCT				X
	B20	WO 01/85691 A1	11/15/01	PCT				X
	B21	WO 01/85671 A2	11/15/01	PCT				X

OI	P.E. SOLES
JUN 1	1 1 2003
163.	

1 4 2002	1	Sheet	2	Of	2
. RET	Atty. Docket No.	Serial No.			
RADEMARK	A-733A	1	0/046	6.681	
	Applicant				

Chen et al.

January 10, 2002

LIST OF REFERENCES CITED BY APPLICANT

Modified Form PTO-1449

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Filing Date

	C1	Konshin et al., "Synthesis and antimicrobial activity of arylamic Abstr. 97:109837	des of N-(4-pyridyl)anthranilc acid." (1981) Chem
C2 Singh et al., "Substituted Imidazolines and their CNS Activity" (1992) Ind. J. Het. Chem. 2:12 C3 Seto et al., "Molecular Self-Assembly through Hydrogen Bonding: Supramolecular Aggregat Cyanuric Acid•Melamine Lattice." (1993) J. Amer. Chem. Soc. 115:905-916			(1992) Ind. J. Het. Chem. 2:129-132
C4 Breier et al., "The role of vascular endothelial growth factor in blood vessel formation" (Biology 6:454-456 C5 Connell et al., "Patent focus on cancer chemotherapeutics. II Angiogenesis agents: Ap 2000" (2001) Exp. Opin. Ther. Patents 11:77-114		-	blood vessel formation" (1996) Trends in Cell
		Angiogenesis agents: April 2000 - September	
EXAMINER:			Date Considered:
EXAMINER: Initial communication to		n considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if n t.	ot in conformance and not considered. Include copy of this form with next

Group

1614

RECEIVED
JUN 1 8 2002
TECH CENTER 1600/2900